Nirmatrelvir/ritonavir treatment and the risk of post-COVID condition over 180 days in Malaysia

{ 'indexed': {'date-parts': [[2024, 8, 6]], 'date-time': '2024-08-06T00:22:25Z', 'timestamp': 1722903745226}, 'reference-count': 36, 'publisher': 'Springer Science and Business Media LLC', 'issue': '1', 'license': [ { 'start': { 'date-parts': [[2024, 8, 5]], 'date-time': '2024-08-05T00:00:00Z', 'timestamp': 1722816000000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by-nc-nd/4.0'}, { 'start': { 'date-parts': [[2024, 8, 5]], 'date-time': '2024-08-05T00:00:00Z', 'timestamp': 1722816000000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by-nc-nd/4.0'}], 'funder': [ { 'name': 'Ministry of Health Malaysia Research Grant', 'award': ['NIH/800-3/2/2 Jilid 13 (182)']}], 'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False}, 'DOI': '10.1186/s12879-024-09679-1', 'type': 'journal-article', 'created': {'date-parts': [[2024, 8, 5]], 'date-time': '2024-08-05T06:03:12Z', 'timestamp': 1722837792000}, 'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Nirmatrelvir/ritonavir treatment and the risk of post-COVID condition over 180 days in Malaysia', 'prefix': '10.1186', 'volume': '24', 'author': [ {'given': 'Ee Vien', 'family': 'Low', 'sequence': 'first', 'affiliation': []}, {'given': 'Mohan Dass', 'family': 'Pathmanathan', 'sequence': 'additional', 'affiliation': []}, {'given': 'Yi Yang', 'family': 'Ten', 'sequence': 'additional', 'affiliation': []}, {'given': 'Suresh Kumar', 'family': 'Chidambaram', 'sequence': 'additional', 'affiliation': []}, {'given': 'Wee Ric', 'family': 'Kim', 'sequence': 'additional', 'affiliation': []}, {'given': 'Wei Jia', 'family': 'Lee', 'sequence': 'additional', 'affiliation': []}, {'given': 'Zhi Wei', 'family': 'Teh', 'sequence': 'additional', 'affiliation': []}, {'given': 'Maheshwara Rao', 'family': 'Appannan', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mastura', 'family': 'Ismail', 'sequence': 'additional', 'affiliation': []}, {'given': 'Azah Abdul', 'family': 'Samad', 'sequence': 'additional', 'affiliation': []}, { 'given': 'Kalaiarasu M.', 'family': 'Peariasamy', 'sequence': 'additional', 'affiliation': []}], 'member': '297', 'published-online': {'date-parts': [[2024, 8, 5]]}, 'reference': [ { 'key': '9679_CR1', 'unstructured': 'Ministry of Health Malaysia. COVID-19: What is latest situation in ' 'Malaysia? 2024 https://data.moh.gov.my/dashboard/covid-19. Accessed 15 ' 'Dec 2023.'}, { 'issue': '1', 'key': '9679_CR2', 'doi-asserted-by': 'publisher', 'first-page': '2027160', 'DOI': '10.1080/21645515.2022.2027160', 'volume': '18', 'author': 'I Mohammed', 'year': '2022', 'unstructured': 'Mohammed I, Nauman A, Paul P, Ganesan S, Chen KH, Jalil SMS, et al. The ' 'efficacy and effectiveness of the COVID-19 vaccines in reducing ' 'infection, severity, hospitalization, and mortality: a systematic ' 'review. Hum Vaccin Immunother. 2022;18(1):2027160.', 'journal-title': 'Hum Vaccin Immunother'}, { 'key': '9679_CR3', 'unstructured': 'Centers for Disease Control and Prevention. Benefits of Getting ' 'https://www.cdc.gov/coronavirus/2019-ncov/vaccines/vaccine-benefits.html. ' 'Accessed 15 Dec 2023.'}, { 'key': '9679_CR4', 'unstructured': 'Anand R. PM Muhyiddin receives first Covid-19 vaccine as Malaysia kicks ' 'off mass innoculation campaign. Straits Time. 2021.'}, { 'key': '9679_CR5', 'unstructured': 'Ministry of Health Malaysia. COVIDNOW: Vaccination Progress 2023. ' 'https://covidnow.moh.gov.my/vaccinations/?refresh=1720781109523. ' 'Accessed 1 January 2024.'}, { 'key': '9679_CR6', 'first-page': '100055', 'volume': '4', 'author': 'BLH Sim', 'year': '2020', 'unstructured': 'Sim BLH, Chidambaram SK, Wong XC, Pathmanathan MD, Peariasamy KM, Hor ' 'CP, et al. Clinical characteristics and risk factors for severe COVID-19 ' 'infections in Malaysia: a nationwide observational study. Lancet Reg ' 'Health West Pac. 2020;4:100055.', 'journal-title': 'Lancet Reg Health West Pac'}, { 'key': '9679_CR7', 'unstructured': 'Centers for Disease Control and Prevention. Underlying Medical ' 'Conditions 2023. ' 'https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html. ' 'Accessed 15 Dec 2023.'}, { 'issue': '9', 'key': '9679_CR8', 'doi-asserted-by': 'publisher', 'first-page': 'e1247', 'DOI': '10.1016/S2214-109X(22)00286-8', 'volume': '10', 'author': 'M Dryden', 'year': '2022', 'unstructured': 'Dryden M, Mudara C, Vika C, Blumberg L, Mayet N, Cohen C, et al. ' 'Post-COVID-19 condition 3 months after hospitalisation with SARS-CoV-2 ' 'in South Africa: a prospective cohort study. Lancet Glob Health. ' '2022;10(9):e1247–56.', 'journal-title': 'Lancet Glob Health'}, { 'key': '9679_CR9', 'unstructured': 'Centers for Disease Control and Prevention, Long COVID. 2023. ' 'https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html. ' 'Accessed 15 Dec 2023.'}, { 'key': '9679_CR10', 'doi-asserted-by': 'publisher', 'first-page': '101762', 'DOI': '10.1016/j.eclinm.2022.101762', 'volume': '55', 'author': 'LL O’Mahoney', 'year': '2023', 'unstructured': 'O’Mahoney LL, Routen A, Gillies C, Ekezie W, Welford A, Zhang A, et al. ' 'The prevalence and long-term health effects of long covid among ' 'hospitalised and non-hospitalised populations: a systematic review and ' 'meta-analysis. EClinicalMedicine. 2023;55:101762.', 'journal-title': 'EClinicalMedicine'}, { 'key': '9679_CR11', 'unstructured': 'National Istitue for Health and Care Excellence (NICE). Royal College of ' 'General Practitioner (RCGP); Scottish intercollegiate Guidelines Network ' '(SIGN); COVID-19 rapid guidelines: managing the long term effects of ' 'COVID-19. 2022. Accessed 15 Dec 2023.'}, { 'key': '9679_CR12', 'unstructured': 'Government of Canada. Post COVID-19 condition (long COVID) 2023 [updated ' 'March 9. 2023. ' 'https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/symptoms/post-covid-19-condition.html. ' 'Accessed 15 Dec 2023.'}, { 'key': '9679_CR13', 'unstructured': 'Department of Health and Aged Care, Long COVID. 2023 ' 'https://www.health.gov.au/topics/covid-19/long-covid. Accessed 15 Dec ' '2023.'}, { 'issue': '7', 'key': '9679_CR14', 'doi-asserted-by': 'publisher', 'first-page': 'ofad233', 'DOI': '10.1093/ofid/ofad233', 'volume': '10', 'author': 'M Woodrow', 'year': '2023', 'unstructured': 'Woodrow M, Carey C, Ziauddeen N, Thomas R, Akrami A, Lutje V, et al. ' 'Systematic review of the prevalence of long COVID. Open Forum Infect ' 'Dis. 2023;10(7):ofad233.', 'journal-title': 'Open Forum Infect Dis'}, { 'key': '9679_CR15', 'unstructured': 'FDA. FDA Approves First Oral Antiviral for Treatment of COVID-19 in ' 'Adults. 2023 ' 'https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-antiviral-treatment-covid-19-adults. ' 'Accessed 15 Nov 2023.'}, { 'key': '9679_CR16', 'unstructured': 'Aggarwal NR, Molina KC, Beaty LE, Bennett TD, Carlson NE, Mayer DA et ' 'al. Real-world use of nirmatrelvir-ritonavir in outpatients with ' 'COVID-19 during the era of omicron variants including BA.4 and BA.5 in ' 'Colorado, USA: a retrospective cohort study. The Lancet Infectious ' 'Diseases.'}, { 'issue': '9', 'key': '9679_CR17', 'doi-asserted-by': 'publisher', 'first-page': '790', 'DOI': '10.1056/NEJMoa2204919', 'volume': '387', 'author': 'R Arbel', 'year': '2022', 'unstructured': 'Arbel R, Wolff Sagy Y, Hoshen M, Battat E, Lavie G, Sergienko R, et al. ' 'Nirmatrelvir use and severe Covid-19 outcomes during the Omicron Surge. ' 'N Engl J Med. 2022;387(9):790–8.', 'journal-title': 'N Engl J Med'}, { 'issue': '3', 'key': '9679_CR18', 'doi-asserted-by': 'publisher', 'first-page': 'e342', 'DOI': '10.1093/cid/ciac443', 'volume': '76', 'author': 'R Najjar-Debbiny', 'year': '2022', 'unstructured': 'Najjar-Debbiny R, Gronich N, Weber G, Khoury J, Amar M, Stein N, et al. ' 'Effectiveness of Paxlovid in reducing severe coronavirus Disease 2019 ' 'and mortality in high-risk patients. Clin Infect Dis. 2022;76(3):e342–9.', 'journal-title': 'Clin Infect Dis'}, { 'key': '9679_CR19', 'doi-asserted-by': 'crossref', 'unstructured': 'Wai AK-C, Chan CY, Cheung AW-L, Wang K, Chan SC-L, Lee TT-L et al. ' 'Association of Molnupiravir and Nirmatrelvir-Ritonavir with preventable ' 'mortality, hospital admissions and related avoidable healthcare system ' 'cost among high-risk patients with mild to moderate COVID-19. Lancet Reg ' 'Health – Western Pac. 2023;30.', 'DOI': '10.1016/j.lanwpc.2022.100602'}, { 'key': '9679_CR20', 'doi-asserted-by': 'crossref', 'unstructured': 'Marzi M, Vakil MK, Bahmanyar M, Zarenezhad E, Paxlovid. Mechanism of ' 'action, synthesis, and in Silico Study. Biomed Res Int. ' '2022;2022:7341493.', 'DOI': '10.1155/2022/7341493'}, { 'issue': '1', 'key': '9679_CR21', 'doi-asserted-by': 'publisher', 'first-page': '19688', 'DOI': '10.1038/s41598-023-46912-4', 'volume': '13', 'author': 'S Congdon', 'year': '2023', 'unstructured': 'Congdon S, Narrowe Z, Yone N, Gunn J, Deng Y, Nori P, et al. ' 'Nirmatrelvir/ritonavir and risk of long COVID symptoms: a retrospective ' 'cohort study. Sci Rep. 2023;13(1):19688.', 'journal-title': 'Sci Rep'}, { 'key': '9679_CR22', 'doi-asserted-by': 'crossref', 'unstructured': 'Xie Y, Choi T, Al-Aly Z. Association of Treatment with Nirmatrelvir and ' 'the risk of Post–COVID-19 Condition. JAMA Internal Medicine; 2023.', 'DOI': '10.1001/jamainternmed.2023.0743'}, { 'key': '9679_CR23', 'unstructured': 'National Pharmaceutical Regulatory Agency. SENARAI PRODUK – PRODUK YANG ' 'TELAH DILULUSKAN OLEH PIHAK BERKUASA KAWALAN DADAH (PBKD.) DALAM ' 'MESYUARAT PBKD KALI KE – 370. 2022.'}, { 'key': '9679_CR24', 'doi-asserted-by': 'crossref', 'unstructured': 'Lewnard JA, McLaughlin JM, Malden D, Hong V, Puzniak L, Ackerson BK, et ' 'al. Effectiveness of nirmatrelvir-ritonavir in preventing hospital ' 'admissions and deaths in people with COVID-19: a cohort study in a large ' 'US health-care system. The Lancet Infectious Diseases; 2023.', 'DOI': '10.1016/S1473-3099(23)00118-4'}, { 'key': '9679_CR25', 'doi-asserted-by': 'crossref', 'unstructured': 'Lai CC, Wang YH, Chen KH, Chen CH, Wang CY. The clinical efficacy and ' 'safety of anti-viral agents for non-hospitalized patients with COVID-19: ' 'a systematic review and network Meta-analysis of Randomized controlled ' 'trials. Viruses. 2022;14(8).', 'DOI': '10.3390/v14081706'}, { 'issue': '6', 'key': '9679_CR26', 'doi-asserted-by': 'publisher', 'first-page': '639', 'DOI': '10.1016/S1473-3099(23)00056-7', 'volume': '23', 'author': 'CKH Wong', 'year': '2023', 'unstructured': 'Wong CKH, Lau KTK, Leung GM. Real-world effectiveness of ' 'nirmatrelvir/ritonavir against BA.4 and BA.5 omicron SARS-CoV-2 ' 'variants. Lancet Infect Dis. 2023;23(6):639–40.', 'journal-title': 'Lancet Infect Dis'}, { 'key': '9679_CR27', 'doi-asserted-by': 'publisher', 'first-page': '77', 'DOI': '10.1016/j.ijid.2023.08.003', 'volume': '135', 'author': 'EV Low', 'year': '2023', 'unstructured': 'Low EV, Pathmanathan MD, Chidambaram SK, Kim WR, Lee WJ, Teh ZW, et al. ' 'Real-world nirmatrelvir-ritonavir outpatient treatment in reducing ' 'hospitalization for high-risk patients with COVID-19 during Omicron ' 'BA.4, BA.5 and XBB subvariants dominance in Malaysia: a retrospective ' 'cohort study. Int J Infect Dis. 2023;135:77–83.', 'journal-title': 'Int J Infect Dis'}, { 'issue': '6', 'key': '9679_CR28', 'doi-asserted-by': 'publisher', 'first-page': '807', 'DOI': '10.7326/M22-3565', 'volume': '176', 'author': 'KL Bajema', 'year': '2023', 'unstructured': 'Bajema KL, Berry K, Streja E, Rajeevan N, Li Y, Mutalik P, et al. ' 'Effectiveness of COVID-19 Treatment with Nirmatrelvir-Ritonavir or ' 'Molnupiravir among U.S. veterans: Target Trial Emulation Studies with ' 'one-Month and Six-Month outcomes. Ann Intern Med. 2023;176(6):807–16.', 'journal-title': 'Ann Intern Med'}, { 'issue': '9596', 'key': '9679_CR29', 'doi-asserted-by': 'publisher', 'first-page': '1453', 'DOI': '10.1016/S0140-6736(07)61602-X', 'volume': '370', 'author': 'E von Elm', 'year': '2007', 'unstructured': 'von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. ' 'The strengthening the reporting of Observational studies in Epidemiology ' '(STROBE) statement: guidelines for reporting observational studies. ' 'Lancet. 2007;370(9596):1453–7.', 'journal-title': 'Lancet'}, { 'key': '9679_CR30', 'unstructured': 'Ministry of Health Malaysia. Clinical Management of Confirmed COVID-19 ' 'Case in Adult and Paediatric 2022. ' 'https://covid-19.moh.gov.my/garis-panduan/garis-panduan-kkm/ANNEX-2E-CLINICAL-MANAGEMENT-OF-CONFIRMED-COVID-19-31052022.pdf. ' 'Accessed 15 Nov 2023.'}, { 'issue': '1', 'key': '9679_CR31', 'doi-asserted-by': 'publisher', 'first-page': 'e0296488', 'DOI': '10.1371/journal.pone.0296488', 'volume': '19', 'author': 'PSK Tok', 'year': '2024', 'unstructured': 'Tok PSK, Kang KY, Ng SW, Ab Rahman N, Syahmi MA, Pathmanathan MD, et al. ' 'Post COVID-19 condition among adults in Malaysia following the Omicron ' 'wave: a prospective cohort study. PLoS ONE. 2024;19(1):e0296488.', 'journal-title': 'PLoS ONE'}, { 'key': '9679_CR32', 'unstructured': 'World Health Organization. Post COVID-19 condition (COVID-19) 2022 ' 'https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition. ' 'Accessed 15 November 2023.'}, { 'issue': '1', 'key': '9679_CR33', 'doi-asserted-by': 'publisher', 'first-page': '7363', 'DOI': '10.1038/s41467-022-35240-2', 'volume': '13', 'author': 'K Magnusson', 'year': '2022', 'unstructured': 'Magnusson K, Kristoffersen DT, Dell’Isola A, Kiadaliri A, Turkiewicz A, ' 'Runhaar J, et al. Post-covid medical complaints following infection with ' 'SARS-CoV-2 omicron vs Delta variants. Nat Commun. 2022;13(1):7363.', 'journal-title': 'Nat Commun'}, { 'issue': '1', 'key': '9679_CR34', 'doi-asserted-by': 'publisher', 'first-page': '133', 'DOI': '10.1093/infdis/jiad382', 'volume': '229', 'author': 'P Hedberg', 'year': '2024', 'unstructured': 'Hedberg P, Nauclér P. Post-COVID-19 Condition after SARS-CoV-2 ' 'infections during the Omicron Surge vs the Delta, Alpha, and wild type ' 'periods in Stockholm, Sweden. J Infect Dis. 2024;229(1):133–6.', 'journal-title': 'J Infect Dis'}, { 'issue': '2', 'key': '9679_CR35', 'doi-asserted-by': 'publisher', 'first-page': 'e12', 'DOI': '10.1016/S2213-2600(22)00501-X', 'volume': '11', 'author': 'C Saunders', 'year': '2023', 'unstructured': 'Saunders C, Sperling S, Bendstrup E. A new paradigm is needed to explain ' 'long COVID. Lancet Respiratory Med. 2023;11(2):e12–3.', 'journal-title': 'Lancet Respiratory Med'}, { 'issue': '7', 'key': '9679_CR36', 'doi-asserted-by': 'publisher', 'first-page': 'e28951', 'DOI': '10.1002/jmv.28951', 'volume': '95', 'author': 'TH Liu', 'year': '2023', 'unstructured': 'Liu TH, Wu JY, Huang PY, Tsai YW, Lai CC. The effect of ' 'nirmatrelvir-ritonavir on the long-term risk of neuropsychiatric ' 'sequelae following COVID-19. J Med Virol. 2023;95(7):e28951.', 'journal-title': 'J Med Virol'}], 'container-title': 'BMC Infectious Diseases', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://link.springer.com/content/pdf/10.1186/s12879-024-09679-1.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/article/10.1186/s12879-024-09679-1/fulltext.html', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/content/pdf/10.1186/s12879-024-09679-1.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2024, 8, 5]], 'date-time': '2024-08-05T06:03:53Z', 'timestamp': 1722837833000}, 'score': 1, 'resource': { 'primary': { 'URL': 'https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-024-09679-1'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2024, 8, 5]]}, 'references-count': 36, 'journal-issue': {'issue': '1', 'published-online': {'date-parts': [[2024, 12]]}}, 'alternative-id': ['9679'], 'URL': 'http://dx.doi.org/10.1186/s12879-024-09679-1', 'relation': {}, 'ISSN': ['1471-2334'], 'subject': [], 'container-title-short': 'BMC Infect Dis', 'published': {'date-parts': [[2024, 8, 5]]}, 'assertion': [ { 'value': '31 May 2024', 'order': 1, 'name': 'received', 'label': 'Received', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '29 July 2024', 'order': 2, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '5 August 2024', 'order': 3, 'name': 'first_online', 'label': 'First Online', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, {'order': 1, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Declarations'}}, { 'value': 'This study was registered in the National Medical Research Register and ' 'approved by the Medical Research and Ethics Committee, Ministry of Health ' 'Malaysia (NMRR ID-22-00938-2YN).', 'order': 2, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Ethical approval'}}, { 'value': 'The databases consist of individual-level information. The deidentified data ' 'that support the findings of this study are available upon reasonable request, ' 'and with protocol approved by the Medical Research and Ethics Committee, ' 'Ministry of Health Malaysia.', 'order': 3, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Data sharing statement'}}, { 'value': 'The authors declare no competing interests.', 'order': 4, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Competing interests'}}, { 'value': 'The authors declare that they have no conflict of interests.', 'order': 5, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Conflict of interest'}}], 'article-number': '780'}